iRhythm (IRTC) Technologies announced that the results of the Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy, EXAMINE-HCM, study have been published in Heart Rhythm Journal. The findings were also presented at the Heart Rhythm Society’s annual meeting in 2023, and most recently, at the International HCM Summit 8 in Boston, MA. The newly published research highlights the value of 14-day long-term, uninterrupted continuous monitoring, LTCM, using a Zio XT patch ECG device, for detecting nonsustained ventricular tachycardia, NSVT, a known marker for sudden cardiac death, SCD, in patients with hypertrophic cardiomyopathy, HCM. The findings support more informed decisions about care pathways and interventions, particularly by capturing arrhythmias that would go undetected by standard 48-hour monitoring, such as with a conventional Holter device monitoring period.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IRTC:
- Is IRTC a Buy, Before Earnings?
- Closing Bell Movers: Deckers up 12% after earnings beat
- iRhythm price target raised to $95 from $80 at Truist
- Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide
- iRhythm: FDA clears design updates previously made to Zio AT device
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
